ArticleScientific reports2021
Delivery of functional exogenous proteins by plant-derived vesicles to human cells in vitro.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 2 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- A Systematic Review on Plant-Derived Extracellular Vesicles as Drug Delivery Systems.International journal of molecular sciences · 2024Pooled it
- Exosome-like nanoparticles derived from fruits, vegetables, and herbs: innovative strategies of therapeutic and drug delivery.Theranostics · 2024Pooled it
- Beyond spherical vesicles: morphological diversity of extracellular vesicles in health and disease.Annals of medicine · 2026Review
- Olive leaf-derived exosome-like vesicles attenuate neurotoxicity in an in vitro rotenone model of Parkinson's disease.Metabolic brain disease · 2026Article
- Extracellular vesicle-mediated crosstalk in bone: miR-150-5p as a mechanosensitive regulator of osteoclastogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Mechanisms and Translational Potential of Plant-Derived Extracellular Vesicles in Cardiovascular Disease.Cells · 2026Review
- Progress, Challenges, and Standardization Pathways in the Isolation and Purification Techniques of Plant-Derived Vesicles.Plants (Basel, Switzerland) · 2026Review
- Green nanomedicine for cancer therapy.Chinese medical journal · 2026Review
- Article
- Therapeutic exosomes in cancer: efficacy and safety perspectives.RSC advances · 2026Review
- Cargo-driven extracellular vesicles as pharmaceutical nanocarriers: A pharmaceutics-oriented comparison of animal exosomes and plant-derived exosome-like nanoparticles.International journal of pharmaceutics: X · 2026Review
- Engineering Strategies for Plant-Derived Extracellular Vesicles: Modification, Drug Delivery Performance, and Synergistic Effects with Gel Composite Systems.Pharmaceutics · 2026Review
- Extraction and Isolation of Extracellular Vesicles FromBio-protocol · 2026Article
- Plant-derived nanovesicles: the intelligent nanoplatforms for therapeutics and drug delivery.Journal of nanobiotechnology · 2026Review
- Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.Journal of nanobiotechnology · 2026Review
- Plant-derived extracellular vesicles as tools and targets for inflammatory diseases.Journal of nanobiotechnology · 2026Review
- Protocol for isolating plant-derived extracellular vesicles.STAR protocols · 2026Article
- Plant-Derived Nanocarriers for Drug Delivery: A Unified Framework Integrating Extracellular Vesicles, Engineered Phytocarriers, Hybrid Platforms, and Bioinspired Systems.Plants (Basel, Switzerland) · 2026Review
- Carrot extracellular nanovesicles as carotenoid carriers in an in vitro macular degeneration model.Scientific reports · 2026Article
- Flow Cytometry Role in Unlocking New Frontiers for Nanomedicine Applications of Plant-Derived Vesicles.Journal of extracellular biology · 2026Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-derived extracellular vesicles (EVs) gain more and more attention as promising carriers of exogenous bioactive molecules to the human cells. Derived from various edible sources, these EVs are remarkably biocompatible, biodegradable and highly abundant from plants. In this work, EVs from grapefruit juice were isolated by differential centrifugation followed by characterization of their size, quantity and morphology by nanoparticle tracking analysis, dynamic light scattering, atomic force microscopy and cryo-electron microscopy (Cryo-EM). In Cryo-EM experiments, we visualized grapefruit EVs with the average size of 41 ± 13 nm, confirmed their round-shaped morphology and estimated the thickness of their lipid bilayer as 5.3 ± 0.8 nm. Further, using cell culture models, we have successfully demonstrated that native grapefruit-derived extracellular vesicles (GF-EVs) are highly efficient carriers for the delivery of the exogenous Alexa Fluor 647 labeled bovine serum albumin (BSA) and heat shock protein 70 (HSP70) into both human peripheral blood mononuclear cells and colon cancer cells. Interestingly, loading to plant EVs significantly ameliorated the uptake of exogenous proteins by human cells compared to the same proteins without EVs. Most importantly, we have confirmed the functional activity of human recombinant HSP70 in the colon cancer cell culture upon delivery by GF-EVs. Analysis of the biodistribution of GF-EVs loaded with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.